Biological Factors in Predicting Response to Treatment in Patients With Esophageal Cancer or Rectal Cancer
NCT ID: NCT00628368
Last Updated: 2024-07-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
160 participants
INTERVENTIONAL
2005-11-30
2009-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This clinical trial is studying how well biological factors work in predicting response to treatment in patients with esophageal cancer or rectal cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Genes in Predicting Outcome in Patients With Esophageal Cancer Treated With Cisplatin, Radiation Therapy, and Surgery
NCT00898495
Predictive Proteomic Factors of the Response to Concomitant Radiochemotherapy in Esophageal Cancer
NCT00911092
Pre-operative Chemotherapy and Radiation Therapy for Esophageal Carcinoma
NCT00230451
Phase II Study of Pre-Operative Chemotherapy in Patients With Resectable Local-Regional Carcinoma of Esophagus
NCT00208936
Genetic and Environmental Risk Factors Related to Esophageal Cancer
NCT01035398
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary
* Analyze various biological factors that can be used as markers to predict response to treatment and correlate with the signaling pathway of EGFR.
Secondary
* Establish a tissue bank to store information about the response to treatment and survival.
OUTLINE: Patients undergo endoscopy, 11 biopsies of tumor tissue, and 3 biopsies of healthy mucosa. Blood samples are also collected. Samples are analyzed for the expression of 4 receptors in the EGFR family, polymorphisms at intron 1 of the EGFR gene, and gene mutations in downstream signaling pathways.
After surgery, patients are followed every 3 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
DIAGNOSTIC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
gene expression analysis
mutation analysis
polymorphism analysis
laboratory biomarker analysis
biopsy
endoscopic biopsy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically confirmed adenocarcinoma or squamous cell carcinoma of the esophagus or rectum
* Planning to receive neoadjuvant treatment, including radiotherapy or chemoradiotherapy
PATIENT CHARACTERISTICS:
* Not pregnant or nursing
* No blood disorder
* Not deprived of freedom or protected by law
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
18 Years
120 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut du Cancer de Montpellier - Val d'Aurelle
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marc Ychou, MD, PhD
Role: STUDY_CHAIR
Institut du Cancer de Montpellier - Val d'Aurelle
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
Montpellier, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLCC-EGFR-BIO
Identifier Type: -
Identifier Source: secondary_id
INCA-RECF0366
Identifier Type: -
Identifier Source: secondary_id
CDR0000574175
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.